Company Overview and News

 
Bombardier receives order as Siemens' partner and supplier in the expansion of Deutsche Bahn's ICE 4 fleet

2018-10-04 globenewswire
Note to editors: To view the photo associated with this press release, please visit the following link:
BDRPF

 
Bombardier erhält Auftrag als Partner und Lieferant von Siemens beim Ausbau der ICE 4-Flotte der Deutschen Bahn

2018-10-04 globenewswire
der globale Anbieter von Mobilitätslösungen Bombardier Transportation leistet auch in Zukunft als Partner und Lieferant von Siemens einen wichtigen Beitrag für den Ausbau der ICE-4-Flotte der Deutschen Bahn. Ende September hat Bombardier mit Siemens einen Vertrag über die weitere Zusammenarbeit als Lieferant für die neue Bestellung der Deutschen Bahn über 18 7-teilige ICE-4-Züge und 50 Triebwagen unterzeichnet.
BDRPF

 
Bombardier double ses capacités de service à la clientèle en Floride avec un nouveau centre de services dans le comté de Miami-Dade pour les clients des États-Unis et d’Amérique latine

2018-10-03 globenewswire
MIAMI, 03 oct. 2018 (GLOBE NEWSWIRE) -- Bombardier a l’honneur d’annoncer une autre vague de croissance de son réseau de service de premier ordre, alors qu’elle accroît les capacités de son service à la clientèle aux États-Unis avec un nouveau centre de services à l’aéroport Miami-Opa Locka Executive Airport (OPF) dans le comté de Miami-Dade, en Floride. Le nouveau centre de services fera plus que doubler l’empreinte actuelle du service à la clientèle de la société en Floride avec de nouvelles capacités, dont un atelier de peinture pour la vaste clientèle du centre couvrant les États-Unis et l’Amérique latine.
BDRPF

 
EXL Announces $150 Million Strategic Investment from The Orogen Group

2018-10-02 globenewswire
NEW YORK, Oct. 02, 2018 (GLOBE NEWSWIRE) -- EXL (NASDAQ: EXLS), a leading operations management and analytics company, today announced that on October 1, 2018 EXL entered into an Investment Agreement under which The Orogen Group (“Orogen”) will, on or about October 4, 2018 and subject to the completion of customary closing conditions, purchase from EXL 3.50% Convertible Senior Notes, due 2024 (the “Convertible Notes”) in an aggregate principal amount of $150 million.
EXLS BDRPF MS VRTU

 
PRESS DIGEST- Canada - Oct. 1

2018-10-01 reuters
Oct 1 (Reuters) - The following are the top stories from selected Canadian newspapers. Reuters has not verified these stories and does not vouch for their accuracy.
HSE MEG BDRPF MEGEF HUSKF

 
Bombardier CRJ Series obtiene certificación para intervalos de mantenimiento más largos

2018-09-25 globenewswire
MONTREAL, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Bombardier Commercial Aircraft anunció hoy que la Agencia Federal de Aviación (Federal Aviation Agency, FAA) ha otorgado la aprobación para extender los intervalos de mantenimiento de los aviones CRJ700, CRJ900 y CRJ1000. El intervalo de mantenimiento de línea (verificación A) se extiende a 800 horas de vuelo y el intervalo de mantenimiento pesado (verificación C) a 8000 horas de vuelo.
BDRPF

 
Les avions Bombardier CRJ Series certifiés pour un accroissement des intervalles de maintenance

2018-09-24 globenewswire
MONTRÉAL, 24 sept. 2018 (GLOBE NEWSWIRE) -- Bombardier Avions commerciaux a annoncé aujourd’hui que la Federal Aviation Agency (FAA) a donné son approbation relativement à l’accroissement des intervalles de maintenance pour les avions CRJ700, CRJ900 et CRJ1000. Les intervalles de maintenance en piste (visite A) et de révision générale (visite C) sont prolongés à 800 et à 8 000 heures de vol respectivement.
BDRPF

 
Bombardier entrega la primera aeronave Q400 de 90 plazas a SpiceJet

2018-09-24 globenewswire
TORONTO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Bombardier Commercial Aircraft ha anunciado hoy la entrega de su primera aeronave Q400 de 90 plazas. La aeronave se ha entregado a la compañía india SpiceJet Limited ("SpiceJet"), el operador de lanzamientos para la aeronave con capacidad extra de 90 plazas.
BDRPF

 
봄바디어, 90석 규모 Q400 항공기 첫 생산분 스파이스젯에 인도

2018-09-24 globenewswire
캐나다 토론토, Sept. 24, 2018 (GLOBE NEWSWIRE) -- 봄바디어 커머셜 에어크래프트(Bombardier Commercial Aircraft)는 90석 규모 Q400 항공기 첫 생산분을 인도했다고 밝혔다. 항공기는 90석으로 좌석 배치를 확장한 본 기종의 최초 운영사인 인도 항공사 스파이스젯(SpiceJet Limited)에 인도되었다.
BDRPF

 
Bombardier Menghantar Pesawat Q400 Dengan 90 Tempat Duduk Pertama Kepada SpiceJet

2018-09-24 globenewswire
TORONTO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Pesawat Komersial Bombardier mengumumkan penghantaran pesawat Q400 dengan 90 tempat duduk pertama hari ini. Pesawat tersebut diberikan kepada SpiceJet Limited India (“SpiceJet”), pengendali pelancaran pesawat itu.
BDRPF

 
Bombardier Delivers First 90-seat Q400 Aircraft to SpiceJet

2018-09-21 globenewswire
TORONTO, Sept. 21, 2018 (GLOBE NEWSWIRE) -- Bombardier Commercial Aircraft today announced the delivery of its first 90-seat Q400 aircraft. The aircraft was handed over to India’s SpiceJet Limited (“SpiceJet”) the launch operator for the extra-capacity, 90-seat aircraft.
BDRPF

 
Bombardier livre le premier avion Q400 de 90 places à SpiceJet

2018-09-21 globenewswire
TORONTO, 21 sept. 2018 (GLOBE NEWSWIRE) -- Bombardier Avions commerciaux a annoncé aujourd’hui la livraison de son tout premier biturbopropulseur Q400 de 90 places. L’avion a été remis au transporteur indien SpiceJet Limited (« SpiceJet »), exploitant de lancement de cet avion à capacité accrue de 90 places.
BDRPF

 
ÖBB Cityjet TALENT3 erstmalig auf der InnoTrans in Berlin ausgestellt

2018-09-19 globenewswire
Sichere und komfortable Züge, die zu einem modernen Lebensstil passen – nicht weniger erwarten die Fahrgäste von den ÖBB. Um diesen Ansprüchen Rechnung zu tragen, sind laufende Investitionen und eine regelmäßige Erneuerung des Fuhrparks zentrale Voraussetzungen. Der hochmoderne und flexible ÖBB Cityjet vom Typ BOMBARDIER TALENT 3 ist die Antwort und soll in Vorarlberg und Tirol zum Einsatz kommen. Präsentiert wird der erste fertige Zug gemeinsam mit dem Hersteller Bombardier Transportation auf der InnoTrans – der internationalen Fachmesse für Bahn- und Verkehrstechnik.
BDRPF

 
Le train Cityjet de type TALENT3 des Chemins de fer fédéraux autrichiens (ÖBB) présenté en grande première à la foire InnoTrans de Berlin

2018-09-19 globenewswire
Note aux rédacteurs : Pour voir les photos associées à ce communiqué, veuillez visiter les liens suivants : http://www.globenewswire.com/NewsRoom/AttachmentNg/8d71d897-1a4f-4f90-8c1f-53677683b95c/fr http://www.globenewswire.com/NewsRoom/AttachmentNg/177d84af-af54-46c1-bcfe-4b2ec31c6fd6/fr http://www.globenewswire.com/NewsRoom/AttachmentNg/568499c4-2383-488f-9436-78d5ea484907/fr http://www.globenewswire.
BDRPF

 
PRESS DIGEST- Canada-Sept 18

2018-09-18 reuters
Sept 18 (Reuters) - The following are the top stories from selected Canadian newspapers. Reuters has not verified these stories and does not vouch for their accuracy.
BDRPF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 097751BF7